Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

CARsgen Therapeutics' (satricabtagene autoleucel) wins NMPA approval targeting Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma after Ph2 success
Cell therapy, cancer, CAR-T, gastric cancer, Claudin18.2, solid tumor - Read more

Sanofi's Cenrifki (tolebrutinib) wins EU approval for secondary progressive multiple sclerosis based on Ph3 data
Small molecule, neurological, BTK inhibitor, multiple sclerosis, secondary progressive multiple sclerosis, tolebrutinib - Read more

Pierre Fabre's Braftovi (encorafenib) wins EC approval for first-line BRAF V600E-mutant metastatic colorectal cancer following Ph3 success
Small molecule, cancer, colorectal cancer, BRAF V600E mutation, combination therapy, first-line treatment - Read more

AbbVie's Skyrizi (risankizumab) wins EC approval for pediatric moderate to severe plaque psoriasis after Ph3 data
Biologics, autoimmune, monoclonal antibody, plaque psoriasis, IL-23 inhibitor, pediatric patients - Read more

Gilead Sciences' Trodelvy (sacituzumab govitecan) receives EU approval for first-line unresectable or metastatic triple-negative breast cancer based on Ph3 data
Antibody-drug conjugate, cancer, triple-negative breast cancer, TROP2, monoclonal antibody - Read more

Merck KGaA, Versant Ventures launch Saturnus Bio for rare genetic heart diseases with $50M commitment, acquisition option
Equity investment, rare disease, cardiovascular, antibody, milestone payments, acquisition - Read more

Nuvectis, Haisco Pharmaceutical ink deal for two late-stage programs, $40M upfront, up to $1.42B milestones
Licensing deal, rare disease, oncology, small molecule, milestone payments, royalties - Read more

Bayer, Iambic Therapeutics partner on AI-driven small-molecule discovery for hard-to-drug targets
Licensing deal, AI/ML, small molecule, drug discovery, milestone payments - Read more

TrueLab Biopharmaceutical, Bionyra Pharma license two antibodies for inflammatory diseases, up to $985M
Licensing deal, autoimmune, antibody, AI/ML, milestone payments, equity investment - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Corxel Pharmaceuticals' CX11 (oral GLP-1 small molecule) hits Ph2 primary endpoints for obesity with 11.5% weight loss
Small molecule, metabolic, GLP-1 receptor agonist, obesity, oral drug delivery - Read more

DropGenie raises undisclosed Seed+ financing to commercialize next-generation gene editing platform
Gene editing, platform technology, cell therapy, functional genomics, AI/ML platform - Read more

Ligand Pharmaceuticals prices upsized $625M convertible notes offering due 2031
Royalty aggregator, biopharmaceutical, platform technology, drug formulation - Read more

Trimtech Therapeutics raises additional $14M Seed funding, developing small molecule neurodegenerative disease therapies
Small molecule, neurological, protein degradation, Alzheimer disease, preclinical - Read more

ChemT Biotechnology raises $4M Seed funding, advancing AI-driven biomanufacturing intelligence platform
AI-driven, biomanufacturing, small molecule, cell therapy, platform technology - Read more

Eli Lilly's tirzepatide leads obesity-driven forecast of $2T global drug sales by 2032
GLP-1, obesity, financial, competitive, strategic - Read more

HHS, FDA launch "unprecedented" initiative to cut clinical trial timelines, restore U.S. drug development leadership
Clinical trial reform, oncology, rare disease, regulatory, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Sangamo files for bankruptcy, lines up Eli Lilly and Astellas as stalking horse bidders for substantially all assets
Acquisition, gene therapy, rare disease, bankruptcy, cell therapy - Read more

Exelixis' (zanzalintinib) Ph3 trial misses colorectal cancer endpoint, but FDA approval still anticipated
Small molecule, cancer, multikinase inhibitor, colorectal cancer, combination therapy, PD-L1 - Read more

Pfizer's (sigvotatug vedotin) fails Ph3 overall survival endpoint in non-small cell lung cancer
Antibody-drug conjugate, cancer, non-small cell lung cancer, integrin beta-6, combination therapy, PD-1 inhibitor - Read more

Genentech, Novartis accused in whistleblower suit of decades-long kickback scheme promoting Xolair
Monoclonal antibody, autoimmune, kickback scheme, Medicare/Medicaid fraud - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here